Leaders Cosmetics

Leaders Cosmetics was established in 1986 and listed on KOSDAQ in 2003, and it operates an unusual dual structure spanning cosmetics and corrugated-board packaging.

In its most recent fiscal year, corrugated board (double-faced, double-wall and single-faced board) accounted for roughly 67% of revenue and effectively served as the company's core revenue base, while cosmetics products such as mask packs and basic skincare made up about 21% and merchandise sales about 11%.

The cosmetics unit positions itself as a cosmeceutical specialist built on clinical experience from the affiliated Leaders Dermatology Clinic, manufacturing products through an integrated planning-R&D-production-distribution system at its Aqua factory, which the company describes as the largest domestic facility dedicated to mask-pack production.

Products are sold in roughly 30 countries through drugstores, supermarkets, convenience stores, department stores and duty-free channels.

The corrugated-board business was spun off into a separate entity, Sansung P&C, in 2016 and then re-absorbed back into Leaders Cosmetics in 2022, reconstituting the dual-business structure under one listed entity.

The cosmetics industry is described as facing intensifying competition from new entrants, while the corrugated-board business continues to see modest growth on the back of rising packaging demand from e-commerce and substitution demand away from styrofoam.

In March 2026, the company entered the prescription-drug distribution business for the first time by signing a domestic exclusive-sale license agreement with KONEX-listed drug developer EnsolBioscience for the osteoarthritis treatment candidate E1K.

Under the deal, if E1K clears Phase 3 trials and receives final product approval, Leaders Cosmetics would obtain full rights to domestic sales, distribution and marketing, and the company said the agreement secures a new growth driver through a validated drug pipeline.

Consolidated revenue moved from KRW 86.6bn in 2022 to KRW 69.3bn in 2023, KRW 73.5bn in 2024 and KRW 68.3bn in 2025, without establishing a clear growth trajectory.

Operating profit swung from a small KRW 0.5bn gain in 2022 to losses of KRW 4.3bn in 2023 and KRW 2.9bn in 2024, before widening again to a KRW 7.1bn loss in 2025, with the operating margin deteriorating from 0.6% in 2022 to negative 10.4% in 2025.

Net income attributable to owners fluctuated from a loss of KRW 0.76bn in 2022 to a small profit of KRW 0.17bn in 2023, then losses of KRW 3.2bn in 2024 and KRW 8.3bn in 2025, showing no consistent improvement trend.

On a quarterly basis, revenue fell from KRW 19.5bn in Q2 2025 to KRW 18.9bn in Q3 and KRW 11.6bn in Q4, marking a seasonal trough, while the operating loss widened to KRW 3.1bn in Q4.

In 2026, revenue recovered sequentially to KRW 17.2bn in Q1 and KRW 20.6bn in Q2, but operating losses of KRW 2.3bn and KRW 1.5bn respectively show the company has yet to exit the loss-making phase.

Over the trailing four quarters (Q3 2025 through Q2 2026), net loss attributable to owners totaled roughly KRW 9.2bn, a sizable figure even on an annualized basis.

The balance sheet has weakened in tandem: owners' equity fell from KRW 43.2bn in 2022 to KRW 28.6bn in 2025, a decline of roughly one-third over four years, while the debt ratio rose from 83.5% to 143.0% over the same period.

Operating cash flow swung sharply from positive KRW 3.2bn in 2022 to negative KRW 5.6bn in 2023, positive KRW 0.07bn in 2024 and negative KRW 3.5bn in 2025, underscoring unstable cash generation.

The domestic mask-pack industry once grew rapidly on the back of Chinese tourism and social-media marketing, but industry-wide performance has struggled for years since Chinese sales weakened following the THAAD dispute.

Industry commentary indicates that leading domestic mask-pack makers including Leaders Cosmetics, Jeijun Cosmetics and Zenic have all experienced revenue declines and deteriorating profitability.

More recently, the cosmetics industry is assessed as facing intensified competition from new entrants, and mask packs are cited as a category with low entry barriers and weak brand loyalty given their disposable, single-use nature.

In contrast, the corrugated-board industry is seen as growing modestly, supported by rising packaging demand from e-commerce and substitution demand away from styrofoam.

However, the corrugated-board market is described as a typically fragmented, small-and-medium-enterprise-type industry, since bulky products require production dispersed close to demand centers, leaving persistent competition with larger paper manufacturers.

Credit-rating data classifies Leaders Cosmetics around the 19th position by revenue within the standard corrugated-board manufacturing category, trailing larger players such as Taerim Packaging, Asia Paper and Jeil Industrial, indicating a competitive disadvantage in scale.

The company's biggest recent variable is the domestic exclusive license agreement for E1K signed with EnsolBioscience. The deal involves fixed technology fees, including upfront payments, totaling roughly KRW 100bn, with additional sales-linked royalties to be paid separately once commercial sales begin.

To fund the upfront payment, Leaders Cosmetics decided in March 2026 to dispose of 765,067 treasury shares at KRW 1,477 per share, for a total of roughly KRW 1.13bn, in an over-the-counter sale to EnsolBioscience.

The company stated that the agreement secures a validated new-drug pipeline and a new growth driver, and outlined plans to expand its influence in the pharmaceutical and bio markets going forward.

However, E1K still requires completion of Phase 3 trials and final product approval before it can meaningfully contribute to revenue, meaning commercialization will take additional time.

Partner EnsolBioscience is itself in the process of pursuing a renewed KOSDAQ listing attempt in the second half of 2026, meaning the license deal's downstream progress is intertwined with the partner's listing and funding status.

The existing core businesses of cosmetics and corrugated board remain exposed to a dual squeeze from intensifying competition in cosmetics and cost pressure in corrugated board, leaving open the question of whether the new pipeline can offset structural issues in the core operations.